Wealthspring Capital’s ProKidney PROK Stock Holding History

Wealthspring Capital’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-466,376	Closed	-$4.64M	–	481
2022 Q2	$4.64M	Buy	466,376 +1,181	+0.3%	+$11.7K	0.87%	13
2022 Q1	$4.61M	Buy	465,195 +356,707	+329%	+$3.52M	0.9%	14
2021 Q4	$1.07M	Buy	108,488 +1,603	+1%	+$15.8K	0.23%	164
2021 Q3	$1.05M	Buy	+106,885	New	+$1.05M	0.25%	139

Other funds holding PROK

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

MCM

Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Wealthspring Capital's PROK Position: Q3 2022 in Review

Wealthspring Capital sold out of ProKidney (PROK) in Q3 2022, closing a stake of 466,376 shares — an estimated $4.64M sold.

Wealthspring Capital first reported a position in PROK in Q3 2021 and held it in 4 quarters. The position peaked at $4.64M in Q2 2022. 18 funds tracked by Wall St. Rank hold PROK as of Q3 2022.

Wealthspring Capital reported no remaining ProKidney position as of Q3 2022 after selling out during the quarter.
Wealthspring Capital sold 466,376 ProKidney shares in Q3 2022, an estimated $4.64M.
Wealthspring Capital first reported a position in ProKidney in Q3 2021 and held it in 4 quarters.
Wealthspring Capital's ProKidney position peaked at $4.64M in Q2 2022.
18 funds tracked by Wall St. Rank held ProKidney as of Q3 2022.

Based on Wealthspring Capital's 13F filing for Q3 2022, filed 27 Oct 2022.